Premium
The effect of ticlopidine on canine platelets, fibrinogen, and antithrombin III activity
Author(s) -
BOUDREAUX M. K.,
JEFFERS C.,
LIPSCOMB D.,
SPANO J. S.
Publication year - 1992
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1992.tb00980.x
Subject(s) - platelet , mean platelet volume , antithrombin , fibrinogen , ticlopidine , medicine , chemistry , bleeding time , endocrinology , platelet aggregation , heparin , aspirin , clopidogrel
The effect of ticlopidine on platelet function, platelet number, mean platelet volume, antithrombin III activity, and fibrinogen was evaluated in 10 laboratory beagles. Ticlopidine (62 mg/kg) significantly inhibited ADP‐ and collagen‐induced platelet aggregation within 2 days of the beginning of oral administration. Collagen‐induced platelet 14 C‐serotonin release was not inhibited by day 9 of medication but was inhibited by day 20 in two of three beagles given medication for 32 days. Significant increases in mean platelet number were observed on days 2 and 5. The trend toward increased platelet number continued until day 16, at which time platelet number began to decrease toward baseline in three of three dogs treated for 32 days. Mean platelet volume (MPV) was significantly decreased compared to baseline on days 5 and 9. In three dogs treated for 32 clays, the lowest MPV was observed on day 9 in two dogs and on day 12 in one dog. Significant changes were not observed in antithrombin III activity or fibrinogen with ticlopicline treatment.